iRadimed (IRMD) Expected to Announce Quarterly Earnings on Friday

iRadimed (NASDAQ:IRMD) is expected to post its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $0.55 per share and revenue of $23.47 million for the quarter. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, October 30, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%. The firm had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million.

iRadimed Price Performance

Shares of IRMD opened at $83.93 on Thursday. iRadimed has a one year low of $75.75 and a one year high of $107.90. The firm has a market capitalization of $1.07 billion, a P/E ratio of 46.89 and a beta of 0.91. The business has a fifty day moving average of $85.89 and a 200 day moving average of $92.86.

Insiders Place Their Bets

In related news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the transaction, the director directly owned 19,581 shares in the company, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 34.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IRMD has been the topic of a number of recent research reports. Needham & Company LLC initiated coverage on iRadimed in a report on Tuesday, September 22nd. They issued a “hold” rating on the stock. Wall Street Zen cut iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings upgraded iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.